Avid Bioservices Inc (CDMO)

[entdoc]

Bungler, yes, fully humanized 2C3. 7/22/09: Peregrine Pharmaceuticals and Affitech today announced they have entered into a licensing agreement for antibody therapeutic rights under Peregrine's preclinical anti-VEGF (Vascular Endothelial Growth Factor) antibody program. Under the terms of the agreement, Affitech will license exclusive worldwide rights to develop and commercialize products under Peregrine's selective anti-VEGF intellectual property portfolio, including the fully human antibody r84 [r84 = “a fully human IgG that phenocopies 2C3”, aka “PGN311”, aka “AT001”], which was discovered by Affitech and jointly developed by the companies under an ongoing collaboration. Under the license agreement, Affitech will be responsible for future preclinical and clinical development and potential product commercialization. Peregrine will receive an upfront payment, research fees and future milestone payments potentially totaling in the double-digit millions (US$).